Evaluation of Triage Tests When Existing Test Capacity Is Constrained: Application to Rapid Diagnostic Testing in COVID-19

Janet Bouttell and Neil Hawkins

Objectives. A triage test is used to determine which patients will undergo an existing or “reference” test. This article explores the potential value of using triage tests before reference tests when the capacity of the reference test is constrained. Methods. We developed a simple model with inputs: prevalence, sensitivity, specificity, and reference test capacity. We included a case study of rapid diagnostic tests for SARS-CoV-2 antigens used as triage tests before a reference polymerase chain reaction test. Performance data were obtained from an evaluation performed by an academic center on 425 samples from testing centers in the United Kingdom and Germany. Results. When reference test capacity is constrained, the use of a triage test leads to a relative expansion of the population tested and cases identified; both are higher with a high-specificity triage test. When reference test capacity is not constrained, the potential advantages of introducing a triage test can be assessed using a standard cost-utility framework, balancing the utility of the reduction in the number of reference tests required against the disutility of missed cases associated with the use of a lower-sensitivity triage test. In the constrained case, the advantage of a triage testing strategy in terms of population covered and cases identified is reduced as the prevalence increases. In the unconstrained case, the reduction in reference tests required is reduced and the number of cases missed increase as the prevalence rises. Conclusion. When the availability of the reference test is constrained, tests added in a triage position do not need high levels of accuracy to increase the number of cases diagnosed. This has implications in many disease areas, including COVID-19.

Keywords
diagnostic test, evaluation, triage test, sensitivity, specificity

Highlights
- Where tests are used in a triage position (to determine who undergoes a high-accuracy diagnostic test), lower-accuracy tests can still be useful.
- When there is limited capacity of the high-accuracy diagnostic test, triage testing strategies can increase the population covered and the number of cases identified.
- When the capacity of the high-accuracy diagnostic test is not limited, triage tests can reduce the number of high-accuracy tests required, although this will be at the cost of missed cases.

Date received: September 4, 2020; accepted: April 11, 2021

The potential value of a test with given performance, in terms of specificity and sensitivity, depends on how the test will be used in clinical practice and the disease prevalence in the population of interest. A new test may be used in a variety of ways. It may be used as a replacement for
an existing test, as an add-on to an existing test, or as a triage test. When used as a triage test, the result of the new test determines which patients will then undergo an existing test. These alternative uses are presented in Figure 1.

The introduction of a triage test does not aim to improve the diagnostic accuracy of the current pathway. Rather, it reduces the use of existing tests that may be invasive, cumbersome, or expensive or for which the patient may need to wait for the test, result, or both. A simple form of triage testing is pooling, in which multiple patient samples are included in 1 sample for testing and individual tests are carried out only if the combined sample tests are positive. A practical example of a triage test is a blood test measuring levels of D-dimer in patients with pulmonary embolism. The “reference” diagnostic test is computed tomography (CT), which is highly accurate. However, CT is expensive, requires skilled staff to perform it, and its capacity is constrained, so patients may need to wait before they are tested. Although D-dimer has low specificity (about 50%), it has high sensitivity and negative predictive value (greater than 99% at a prevalence of 22%). This means that although D-dimer does not pick up all patients who are disease negative, when there is a negative result, it is highly likely that the patient is disease negative. Because the test is cheap and there is no waiting time, D-dimer has potential as a triage test to rule out pulmonary embolism.

A further example of a triage testing strategy is in tuberculosis (TB). The existing reference test is problematic in high-burden countries, as it is based on culturing bacteria from sputum samples. This is time-consuming and may miss cases in important patient groups, such as in children and individuals with human immunodeficiency virus as they struggle to produce sputum. The World Health Organization (WHO) set out minimum and optimum test performance targets in a consensus document produced in 2014. As with D-dimer, the target product profile (TPP) prioritized sensitivity (minimum 90%, optimum 95%) over specificity (minimum 70%, optimum 80%) to minimize false-negatives. A recent article described a blood-based triage test in development that is close to meeting the TPP (sensitivity 86% and specificity 69%) in adult patients with persistent cough. By way of example, these test performance statistics would translate to a negative predictive value of 97% at 17% prevalence among patients with cough in Southeast Asia.

We can classify triage tests as either “rule-in” tests, which are intended to confirm that a patient has a specific disease, or as “rule-out” tests, which are intended to confirm that a patient does not have a disease. Rule-in tests require high specificity and rule-out tests require high sensitivity. This relationship is known as the SPIN and SNOUT rule (SPecific test when positive rules IN the disease [SPIN] and Sensitive test when Negative rules OUT the disease [SNOUT]). The extent to which a rule-in or rule-out test is preferred will depend on the

![Figure 1](https://example.com/figure1.png)

**Figure 1** Roles of tests and positions in existing diagnostic pathways.
prior probability of disease and the consequences, both
to the patient and in terms of health care resource use of
false-positives and false-negatives. Both the D-dimer test
and the TB test described above are rule-out tests with
high sensitivity so that negative results are highly predic-
tive of no disease. The rule-out test is useful in this role,
as the consequences of a false-negative are that a serious
condition may go untreated.

In the context of COVID-19 in the European Union
(EU), the WHO currently recommends diagnosis by
molecular tests, which detect the ribonucleic acid (RNA)
of the SARS-CoV-2 virus. These tests require well-
equipped laboratories, highly skilled technologists, and
multiple reagents. Testing capacity has been constrained
by infrastructure limitations and supply shortages in the
EU and is highly likely to be constrained in less devel-
oped countries around the world. WHO has called for
the development of rapid diagnostic tests (RDTs), which
are based on the detection of antigens related to SARS-
CoV-2. Antigen tests aim to detect the presence of viral
proteins expressed by the virus in a specimen taken from
a person’s respiratory tract. How well these tests work
depends on several factors, including the time from onset
of symptoms, the quality of the specimen collected from
the patient, how the sample is stored, transported, and
processed, as well as the design of the test. Based on
experience with other respiratory diseases, WHO esti-
mates that the sensitivity of these tests might be expected
to vary from 34% to 80%. WHO does not currently
recommend the use of antigen RDTs for clinical decision
making but does recommend further research into
antigen-based tests as they have potential diagnostic util-
ity with improved test performance. When testing
resources are constrained, WHO recommends that test-
ing is prioritized for vulnerable patients at risk of serious
disease, health care workers, and the first symptomatic
individuals in a closed setting such as a prison.

In this article, we set out a method of applying quanti-
tative measures such as sensitivity and specificity, as
stated in documents such as WHO TPPs, to particular
diseases and local contexts to provide more meaningful
metrics to decision makers. We use antigen tests for
SARS-CoV-2 as examples to demonstrate that, if facili-
ties for reference testing are restricted, there may be a
role for RDTs to be used as triage tests to enrich the pre-
valence of disease in the population tested using the refer-
ence test and improve the efficiency of the laboratory-
based RNA testing process. This allows a greater number
of cases to be detected than using reference tests (the
RNA testing process) alone. We present a simple model-
ing approach that can be used to explore the use of a
triage test prior to a reference test. We contrast 2
situations in which the availability of the reference test is
capacity constrained or unconstrained. We show that the
relevant metrics of test value, and the value of a test with
given characteristics, vary depending on whether the
existing reference test capacity is constrained or not. We
develop generic models and then apply them in a case
study using test data for an RDT for SARS-CoV-2. We
describe the limitations of these models and the assump-
tions that would be required when using their outcomes
for decision making. We also discuss their evidential
requirements and contrast these with the requirement for
full-blown cost-effectiveness models. The models pre-
sented in this article are not intended to provide definitive
estimates of the clinical value and cost-effectiveness of a
test; this typically require the careful identification and
synthesis of evidence and the development of detailed
decision-analytic or cost-effectiveness models, which
requires both time and significant resource. Such models
are often highly context specific. Rather, the models pre-
sented here are simple models that can be readily used to
provide an indication of the potential value of a test while
it is under development or during some form of expedited
review. Such models are likely to be useful during the
development of a test and provide a guide as to whether
further investment in the development of a test is war-
ranted and what studies are required to provide sufficient
evidence to support the uptake and commercialization of
a test. We are not seeking to evaluate a particular test or
tests for use in a given scenario; rather, we are presenting
a methodological illustration of the different metrics that
are relevant in evaluating triage tests dependent on
whether access to the reference test is or is not con-
strained. The point applies across disease areas.

**Methods**

A decision-analytic model was developed that pre-
dicted true- and false-positive and -negative rates for a
triage test (T) with given sensitivity (SENS), specificity
(SPEC), and prevalence. In this case, we have defined
sensitivity and specificity strictly in terms of the prob-
ability that the triage test predicts positive and negative
test results for a patient receiving the existing or “refer-
ence” test that is used to determine the future treatment
of a patient. In this notation, $P[R^+]$ (probability of
testing positive in the reference test) is effectively the
prevalence, as we are concerned only with positives
and negatives as defined by the reference test. The ref-
ence test may not be 100% accurate, but this is a sim-
plifying assumption made for the purposes of this illus-
tration.
The model is shown in Figure 2.

We have considered 2 use cases. One in which the reference test capacity is constrained and currently fully used and one in which the reference test capacity can be varied in the short term according to demand. In practice, there may exist a third use case in which capacity can be varied only in the mid to long term.

**Capacity-Constrained Reference Test Use Case**

Where the reference capacity is constrained, we can estimate the probability of testing positive at triage testing ($P(T^+)$) as:

\[
SENS = P(T^+ | R^+) \\
SPEC = P(T^- | R^-)
\]
This provides an estimate of the proportion of patients for whom reference testing is indicated following the triage test. The number of patients who can actually be tested will depend on the available capacity.

We can calculate the probability of testing positive at the reference test following a positive result in triage testing as

\[
P[R^+ | T^+] = \frac{P[R^+] \times SENS}{P[R^+] \times SENS + (1 - P[R^+]) \times (1 - SPEC)}
\]

The difference between these proportions represents patients who would have tested positive under the reference test but were unable to receive the test because of the capacity constraint. It is assumed that \( P[R^+] \) is the same for patients who were able to, and not able to, access the reference test.

We can estimate the maximum relative population size (\( \delta_{\text{triage}} \)) that can be tested using the triage testing before the reference test capacity is exhausted:

\[
\delta_{\text{triage}} = \frac{1}{P[T^+]}
\]

We can also estimate the maximum effective relative increase in the population (\( \delta_{\text{effective}} \)) that can be screened using the triage strategy. This is the factor by which the reference test capacity would need to be expanded by for a reference test–only strategy to identify as many cases as the triage strategy.

\[
\delta_{\text{effective}} = \frac{P[R^+ | T^+]}{P[R^+]}
\]

It will be smaller than \( \delta_{\text{triage}} \), as the triage test will identify some false-positives.

This is the maximum effective expansion that could be achieved if 1) there are no constraints on the availability of the triage tests and 2) there are sufficient potential cases to be tested to exhaust the reference test capacity (i.e., \( \delta_{\text{triage}} \) times the reference test capacity).

We can then finally estimate the increase in the probability of identifying a case from the expanded population that arises from the use of the triage test.

\[
P[R^+ | T^+] - P[R^+]
\]

This increased number of cases detected can be traded off against the cost of the triage testing.

**Reference Test Capacity Unconstrained Use Case**

Where the reference capacity is unconstrained, we can estimate the reduction in the number of reference tests undertaken and the number of false-negative results arising from the use of the triage tests.

The reduction in the proportion of patients requiring the reference test following the triage test (the probability that a patient tests negative on the triage test) is given by

\[
1 - (P[R^+] \times SENS + (1 - P[R^+]) \times (1 - SPEC))
\]

The proportion of missed cases, patients who test negative on the triage test but would have tested positive on the reference test, is given by

\[
P[R^+] \times (1 - SENS)
\]

The reduction in the proportion of patients requiring the reference test and cost savings from that reduction will need to be traded off against the missed cases.

### Case Study

We applied this model to an exemplar antigen test from the 137 listed on February 5, 2021, by the nongovernmental organization, the Foundation for Innovative New Diagnostics (FIND)\(^{13}\) (see Table 1). FIND is a global, nonprofit organization funded primarily by donations from international governments and aid foundations. Its aim is to accelerate the development of diagnostics in diseases of poverty.\(^{13}\) During the COVID-19 pandemic, FIND acted as a register of tests in development and has commissioned independent evaluations of some tests.\(^{13}\)

**Table 1** Rapid Diagnostic Tests for SARS-CoV-2: Case Study

| Test Type   | Characteristic | Exemplar Test          | Sensitivity | Specificity |
|-------------|----------------|------------------------|-------------|-------------|
| Rule-in     | High specificity | Coris BioConcept test\(^{14}\) | 50%         | 95.9%       |
| Rule-out    | High sensitivity | Inverse of above       | 95.9%       | 50%         |
All tests evaluated by FIND to date have relatively high specificity. For illustrative purposes, we chose an evaluated test with relatively low sensitivity (Coris BioConcept COVID-19 Ag Respi-Strip) and then contrasted its performance with a hypothetical test with the sensitivity and specificity of the test reversed.

The Coris BioConcept test is a CE-marked antigen test, meaning it conforms with the relevant EU legislation, directive 98/79/EC, on in vitro diagnostic tests. Test performance was taken from the external evaluation report for the test published by FIND on December 10, 2020. Data for the evaluation were collected from 3 sites in the United Kingdom and Germany from May to August 2020. The samples were taken from hospitalized patients in the United Kingdom and from patients suspected as having SARS-CoV-2 infection at a walk-in center in Germany. The prevalence of SARS-CoV-2 infection among the study population was just less than 2%. For the purposes of the case study, we have selected a base-case prevalence of 5% based on the WHO estimate of prevalence in a symptomatic general population and contacts of an index case. Sensitivity analysis was conducted, showing the incremental probability of detection with a triage strategy for the constrained-use case, proportionate reduction in reference case use in the unconstrained-use case, and the false-positive rate for a full range of prevalence (reference test positive) rates. Contour plots are presented showing the maximum relative expansion of reference test coverage in the constrained-use case and the proportionate reduction in reference testing at different levels of sensitivity and specificity (holding prevalence constant at 5%).

There was no specific funding for this study.

Results

Table 2 provides the probability of a positive test at triage for rule-in and rule-out triage strategies, illustrating that the probability of a positive reference test after triage is greatest with a rule-in test (high specificity) at 39.1% as compared with the probability of a positive reference test after triage with a rule-out test at 9.2%. Both triage strategies increase the probability of a positive reference test by enriching the prevalence in the population taking the reference test. Table 3 illustrates the clinical impact of the triage strategies for the constrained-use case and Table 4 for the unconstrained use case. Different metrics are relevant in each use case. Table 3 shows that where reference test capacity is constrained, the relative expansion of the population and the number

| Strategy Parameter | Rule-in Test (Sensitivity 50.0%, Specificity 95.9%) | Rule-out Test (Sensitivity 95.9%, Specificity 50.0%) |
|--------------------|-----------------------------------------------|-----------------------------------------------|
| Probability of positive test at triage | 6.4% | 52.2% |
| Probability of false-negatives at triage | 2.5% | 0.2% |
| Probability of positive reference test | 39.1% | 9.2% |

*The probability of a reference test being positive under a reference test–only strategy is equivalent to prevalence (5% in the base case).
of cases identified is greater with the higher-specificity, rule-in test. Although the number of false-negatives at triage is also greater with the rule-in test because of the lower sensitivity, this does not equate to missed cases, because the total number of cases identified is still higher with the rule-in test because of the expansion of the tested population. For the unconstrained reference capacity case (see Table 4), the higher-specificity rule-in test leads to the greatest reduction in the number of reference tests required; however, the rule-in test also leads to the greatest number of missed cases. The higher sensitivity rule-out test minimizes the number of missed cases but is less efficient in reducing the number of reference tests.

Sensitivity analysis compared the results shown in Tables 2 and 3 (using a base-case prevalence of 5%) for the full range of prevalence. Figures 3 and 4 show the incremental probability of detection with a triage strategy when reference tests are constrained, the proportionate reduction in reference test use when reference tests are unconstrained, and the triage test false-positive rates for rule-in and rule-out tests, respectively, at different levels of prevalence (reference test positive). In the constrained case, there is a greater probability of cases being identified using a triage strategy regardless of the increasing prevalence with our example of a rule-in triage test outperforming the rule-out test because of higher specificity. In the unconstrained case, a triage testing strategy offers a reduction in the reference tests required (and corresponding cost), although this benefit is reduced as the prevalence increases and more confirmatory reference tests are required. Again, the rule-in test outperforms the rule-out test. The benefit from the reduction in reference tests required must be offset against missed cases, which increase as the prevalence rates rise. The rule-out test example demonstrates a smaller increase, as it is more sensitive. Figure 5 provides a contour plot showing the maximum relative expansion of the reference test population in the constrained-use case for different levels of sensitivity and specificity. The plot demonstrates that the expansion of the population needed to exhaust the reference test capacity in the constrained case varies from 1.5 to 20, depending on the specificity and sensitivity of the test. By way of example, with specificity at 80% and sensitivity at 50%, 2.33 times the number of people could be tested using a triage strategy rather than a reference test-only strategy. With a reference test capacity of 1000, 2330 people could be tested under the triage strategy. Figure 6 is a further contour plot showing the proportionate reduction in reference tests required in the unconstrained-use case for different levels of sensitivity and specificity. As a result of introducing triage tests in an unconstrained-use case, the number of reference tests required can be reduced. The proportionate reduction depends on the sensitivity and specificity of the test, as illustrated by Figure 6. By way of example, at 80%
sensitivity and 80% specificity, the reduction in reference tests required is 0.77. If 1000 reference tests are required under the reference test–only strategy, this will be reduced to 230 under a triage strategy, a reduction of 770 reference tests. Both plots assume a prevalence level (reference test positive) of 5%. The contour plots demonstrate the relative importance of specificity over sensitivity in delivering higher population coverage when reference tests are constrained and a higher reduction in reference tests required in the unconstrained-use case. In the unconstrained-use case, lower sensitivity will result in a higher level of missed cases.

**Discussion**

Where the reference test capacity is constrained and triage tests are unconstrained, the assessment of the opportunity cost of a triage strategy depends on the cost of the triage testing and an assessment of the value of the additional cases identified. The number of additional cases identified is maximized by maximizing specificity. Arguably, sensitivity is less important, as false-negatives at triage testing do not directly represent missed cases. As long as there is a sufficient pool of individuals who would not be tested under the reference test–only regime, the
total number of cases identified will be greater under the triage strategy. However, there still may be a cost associated will false-negatives at triage testing if these lead to a change in behavior in those who test negative at triage.

Where the reference test capacity is unconstrained, the assessment of the opportunity cost of a triage strategy depends on the cost of the triage testing, the costs resulting from a reduction in reference testing, and the cost of any false-negatives at triage testing in terms of worse outcomes. The choice of test will depend on the tradeoff between cost savings and missed cases due to false-negatives at triage.

When the availability of the gold standard diagnostic test is constrained, tests added to the diagnostic pathway in a triage position do not necessarily need high levels of accuracy to increase the number of cases diagnosed. This has implications across a wide range of disease areas and is of particular importance during the current COVID-19 pandemic, as decision makers may be able to make use of a wider range of tests, including RDTs, in designing testing strategies where the availability of laboratory-based molecular testing is limited. Our model provides a simple way of assessing whether a particular test may have the potential to increase diagnoses.

Our study has shown that the value of a triage test, in terms of additional cases diagnosed, depends on whether the availability of the gold standard (or reference) test is constrained. Where resource is not constrained, a triage test will result in missed cases and an overall reduction in diagnoses unless its accuracy is high. However, where the availability of the reference test is constrained, there is the potential for tests with relatively low accuracy to improve the levels of diagnosis and reduce missed cases. The levels of test performance required depend on the extent to which the capacity of the reference test is constrained. Levels of test performance can be lower and still deliver benefits as the number of reference tests available is reduced as a proportion of the population to be tested. This finding has relevance across a wide range of diseases and settings. For example, in TB, approximately 3.6 million cases of active disease go undiagnosed each year, partly because of the limited access to confirmatory molecular tests. A further example is in colorectal cancer. In the United Kingdom, demand for colonoscopy is forecast to increase 10% to 15% per year, resulting in capacity constraints, and fecal immunochemical tests have been suggested as a possible triage test in symptomatic patients.

In relation to the COVID-19 pandemic, testing resources have been constrained in many jurisdictions. Required performance levels for RDTs have been set sufficiently high (for example, the Medicines and Healthcare Products Regulatory Agency [MHRA] in the United Kingdom has set desired performance standards of 97% sensitivity and 99% specificity for tests used to aid in the triage of current SARS-CoV-2 infection by detection of RNA or antigens in samples from people of all ages at any point during active infection) that test manufacturers have failed to meet these levels, and some tests have been returned to the manufacturers. It has been suggested that there is a need to be creative in devising a testing strategy. Our findings suggest that there may be scope to use tests with lower performance in some testing pathways, although each situation would need to be assessed on its own merits, with the strategy tailored to the current stage of the outbreak and transmission rate in the testing area.

The evaluation of alternative testing strategies using cost-effectiveness analysis typically requires a complex model with parameter estimates for health outcomes and resource use. This resource-intensive process takes time and expertise, and the results may be difficult to generalize, as diagnostic and clinical pathways vary across and within jurisdictions. The model presented is not intended to be an alternative to full-blown cost-effectiveness analysis, as it does not include costs or the health implications of false-positives and -negatives at either the triage or reference test stage and makes the simplifying assumption that the reference test is 100% accurate. Rather, the model is intended to be used during the development of a test to determine whether further investment is appropriate and to guide the design and evidence-generation strategy. However, a potential further use of the simple model may be to inform decision makers responding to infectious disease, such as the current COVID-19 pandemic, who need to evaluate a large number of tests in a wide range of testing scenarios. The model could help to narrow the range of alternatives to be explored in more detailed modeling.

As far as we are aware, this is the first simple model to demonstrate the benefit of triage tests when the availability of reference tests is constrained. The only inputs required for our model are prevalence, sensitivity and specificity, population, and number of reference tests available. Assuming that the incremental net (accounting for resource use) health benefit for treated positive cases compared with untreated positive cases is greater than the incremental net health benefit for treated negative cases compared with untreated negative cases, maximizing the total number of true-positive reference tests will maximize the net health benefit. In general, treated negative cases will be associated with a negative incremental health benefit, as they will be associated with wasted resources and sometimes harm to patients because of unnecessary treatment.
References

1. Hayen A, Macaskill P, Irwig L, Bossuyt P. Appropriate statistical methods are required to assess diagnostic tests for replacement, add-on, and triage. J Clin Epidemiol. 2010;63(8):883–91.

2. Bossuyt PM, Irwig L, Craig J, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ. 2006;332(7549):1089–92.

3. Ball J, McNally A. Pooled testing for SARS-CoV-2 could provide the solution to UK’s testing strategy. BMJ. 2020;371:m4312.

4. Kaasjager K, Kamphuisen PW, Kramer MH, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing and computed tomography. JAMA. 2006;295(2):172–9.

5. World Health Organization. High Priority Target Product Profiles for New Tuberculosis Diagnostics: Report of a Consensus Meeting. Geneva (Switzerland). World Health Organization; 2014.

6. Ahmad R, Xie L, Pyle M, et al. A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Sci Transl Med. 2019;11(515):eaaw8287.

7. Keefer E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006;444(1):49–57.

8. Baeyens JP, Serrien B, Goossens M, Clijsen R. Questioning the “SPIN and SNOUT” rule in clinical testing. Arch Physiother. 2019;9(1):4.

9. European Centre for Disease Prevention and Control. An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. Stockholm (Sweden): ECDC; 2020. Available from: www.ecdc.europa.eu/sites/default/files/documents/Overview-rapid-test-situation-for-COVID-19-diagnosis-in-the-EU-EEA.pdf. Accessed February 5, 2021.

10. Kavanagh MM, Erondu NA, Tomori O, et al. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet. 2020;395(10238):1735–8.

11. World Health Organization. Advice on the use of immunodiagnostic tests for COVID-19. 2020. Available from: www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19. Accessed February 5, 2021.

12. World Health Organization. Laboratory testing strategy recommendations for COVID-19. Interim guidance. 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf. Accessed February 5, 2021.

13. Foundation for Innovative New Diagnostics (FIND). SARS-COV-2 diagnostic pipeline. 2020. Available from: www.finddx.org/covid-19/pipeline/. Accessed February 5, 2021.

14. Foundation for Innovative New Diagnostics (FIND). Evaluation of Coris BioConcept COVID-19 Ag Respi-Strip. External report. Version 1.2, December 10, 2020. Available from: https://www.finddx.org/wp-content/uploads/2020/12/Coris-RespiStrip-Ag_Public-Report_20201210-v1.2.pdf. Accessed February 5, 2021.

15. World Health Organization. Antigen detection in the diagnosis of SARS-CoV2 infection using rapid immunoassays. 2020. Available from: https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays. Accessed February 5, 2021.

16. Nathavitharana RR, Yoon C, MacPherson P, et al. Guidance for studies evaluating the accuracy of tuberculosis triage tests. J Infect Dis. 2019;220(suppl 3):S116–25.

17. Westwood M, Lang S, Armstrong N, et al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med. 2017;15(1):1–7.

18. Medicines and Healthcare Products Regulatory Agency. Target product profile: point of care SARS COV2 detection tests. 2020. Available from: https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-point-of-care-sars-cov-2-detection-tests. Accessed February 5, 2021.

19. Adams ER, Augustin Y, Byrne RL, et al. Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration. medRxiv. January 1, 2020. doi:https://doi.org/10.1101/2020.04.29.20082099

20. Jones S. Coronavirus test kits withdrawn in Spain over poor accuracy rate. Guardian. March 27, 2020. Available from: https://www.theguardian.com/world/2020/mar/27/coronavirus-test-kits-withdrawn-spain-poor-accuracy-rate. Accessed February 5, 2021.

21. Pettit SD, Jerome KR, Rouquié D, et al. ‘All in’: a pragmatic framework for COVID-19 testing and action on a global scale. EMBO Mol Med. 2020;12(6):e12634.

22. Peto J. Covid-19 mass testing facilities could end the epidemic rapidly. BMJ. 2020;368:m1163.

23. Rodriguez PF. Predicting whom to test is more important than more tests—modeling the impact of testing on the spread of COVID-19 virus by true positive rate estimation. medRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.04.01.20050393v1. Accessed February 5, 2021.